162 related articles for article (PubMed ID: 33557730)
1. Novel Nitrogen Containing Steroid Derivatives for Prostate Cancer Treatment.
Latysheva AS; Zolottsev VA; Pokrovsky VS; Khan II; Misharin AY
Curr Med Chem; 2021; 28(40):8416-8432. PubMed ID: 33557730
[TBL] [Abstract][Full Text] [Related]
2. Oxazolinyl derivatives of androst-16-ene as inhibitors of CYP17A1 activity and prostate carcinoma cells proliferation: Effects of substituents in oxazolinyl moiety.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Zhdanov DD; Novikov RA; Misharin AY
J Steroid Biochem Mol Biol; 2023 Jun; 230():106280. PubMed ID: 36870373
[TBL] [Abstract][Full Text] [Related]
3. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
[TBL] [Abstract][Full Text] [Related]
4. 17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
Ajduković JJ; Djurendić EA; Petri ET; Klisurić OR; Celić AS; Sakač MN; Jakimov DS; Gaši KM
Bioorg Med Chem; 2013 Dec; 21(23):7257-66. PubMed ID: 24148837
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
Zolottsev VA; Tkachev YV; Latysheva AS; Kostin VA; Novikov RA; Timofeev VP; Morozevich GE; Kuzikov AV; Shumyantseva VV; Misharin AY
Steroids; 2018 Jan; 129():24-34. PubMed ID: 29183745
[TBL] [Abstract][Full Text] [Related]
6. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
7. [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
Audenet F; Murez T; Ripert T; Villers A; Neuzillet Y
Prog Urol; 2013 Oct; 23 Suppl 1():S9-15. PubMed ID: 24314739
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Bordeau BM; Ciulla DA; Callahan BP
ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
12. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
13. Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
De Maeseneer DJ; Van Praet C; Lumen N; Rottey S
Urol Oncol; 2015 Jul; 33(7):310-21. PubMed ID: 25708954
[TBL] [Abstract][Full Text] [Related]
14. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Evaluation of New Isoxazolyl Steroids as Anti-Prostate Cancer Agents.
Rudovich AS; Peřina M; Krech AV; Novozhilova MY; Tumilovich AM; Shkel TV; Grabovec IP; Kvasnica M; Mada L; Zavialova MG; Mekhtiev AR; Jorda R; Zhabinskii VN; Khripach VA
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362320
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Sharma K; Rojas Velazquez MN; Pandey AV; Jørgensen FS; Arendrup FS; Andersen KL; Björkling F
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204665
[TBL] [Abstract][Full Text] [Related]
17. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
18. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Pokrovsky VS; Novikov RA; Timofeev VP; Tkachev YV; Misharin AY
Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
[TBL] [Abstract][Full Text] [Related]
19. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
20. Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls.
Daragan G; Hoffmann J; Vasko T; Mustea A; Burchardt M; Kraus T; Stope MB; Ziegler P
Invest New Drugs; 2020 Apr; 38(2):541-545. PubMed ID: 31292837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
